Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/IIa Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers

NCT02583542 is registered in ClinicalTrials.gov with Queen Mary University of London as lead sponsor.

NCT NCT02583542
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02583542 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/IIa Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers
Lead sponsor
Queen Mary University of London
Phase
Phase 1/2
Overall status
Unknown status
Start date
June 30, 2015
Completion date
March 31, 2020
Enrollment
118 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

non-squamous cell lung cancer with kras mutations, non-squamous cell lung cancer with wild-type kras, squamous cell lung cancer, triple-negative breast cancer